Fractyl Health, Inc. (GUTS) — SEC Filings
Fractyl Health, Inc. (GUTS) — 34 SEC filings. Latest: 8-K (Dec 16, 2025). Includes 19 8-K, 6 10-Q, 4 SC 13G.
View Fractyl Health, Inc. on SEC EDGAR
Overview
Fractyl Health, Inc. (GUTS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: On December 15, 2025, Fractyl Health, Inc. filed an 8-K report detailing a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing was made on December 16, 2025, and pertains to events as of December 15, 2025. The company, previously known as Fractyl Laboratories In
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 2 bearish, 31 neutral, 1 mixed. The dominant filing sentiment for Fractyl Health, Inc. is neutral.
Filing Type Overview
Fractyl Health, Inc. (GUTS) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 1 S-1/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of GUTS's 28 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$45.603M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $77.657M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Paul F. Laikind
- Barry G. Berman
- Joanne E. Smith
- Harith Rajagopalan, M.D., Ph.D.
- Sarah Toomey
Industry Context
The biotechnology sector, particularly companies focused on novel therapeutic approaches like Fractyl Health, is characterized by high R&D investment and long development cycles. Success is heavily dependent on clinical trial outcomes and regulatory approvals. The competitive landscape is intense, with many companies vying for funding and market share in areas with significant unmet medical needs.
Top Tags
disclosure (6) · financials (6) · sec-filing (5) · 8-K (4) · filing (4) · 10-Q (4) · Biotechnology (3) · 8-k (3) · Fractyl Health (3) · Clinical Trials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $45.603M | Increased from $23.173M in Q3 2024, indicating widening losses. |
| Net Loss (9 months 2025) | $97.227M | Increased from $43.724M in 9 months 2024, reflecting accelerated cash burn. |
| Revenue (Q3 2025) | $0 | No revenue generated, down from $14K in Q3 2024, highlighting pre-commercial stage. |
| R&D Expenses (9 months 2025) | $58.043M | Increased from $50.190M in 9 months 2024, showing continued investment in product development. |
| Change in Fair Value of Warrant Liabilities (9 months 2025) | $20.724M | A significant expense, contrasting with a $17.442M gain in the prior year, impacting net loss. |
| Cash and Cash Equivalents (Sept 30, 2025) | $77.657M | Increased from $67.464M at Dec 31, 2024, likely due to recent financing activities. |
| Total Liabilities (Sept 30, 2025) | $117.450M | Significantly increased from $79.653M at Dec 31, 2024, primarily due to warrant liabilities. |
| Common Stock Outstanding (Oct 31, 2025) | 137,044,440 | Reflects potential dilution from recent equity offerings. |
| Net proceeds from the Offering | $20.7M | Received by Fractyl Health from the financing transaction closed on August 7, 2025 |
| Shares of common stock underlying Tranche B Warrants | 21,904,761 | Potential shares to be issued upon exercise, subject to stockholder approval |
| Initial exercise price per share for Tranche B Warrants | $1.05 | The price at which Tranche B Warrants can be exercised |
| Additional gross proceeds if all Tranche B Warrants are cash exercised | $23.0M | Crucial funding for operations and clinical trials if Proposal No. 1 is approved |
| Shares of common stock outstanding | 50,289,014 | As of the Record Date, August 6, 2025 |
| Voting power held by directors, officers, and Mithril | 21% | These parties have agreed to vote in favor of Proposal No. 1 |
| Date of Special Meeting of Stockholders | October 3, 2025 | When stockholders will vote on the proposals |
Frequently Asked Questions
What are the latest SEC filings for Fractyl Health, Inc. (GUTS)?
Fractyl Health, Inc. has 34 recent SEC filings from Jan 2024 to Dec 2025, including 19 8-K, 6 10-Q, 4 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GUTS filings?
Across 34 filings, the sentiment breakdown is: 2 bearish, 31 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Fractyl Health, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Fractyl Health, Inc. (GUTS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Fractyl Health, Inc.?
Key financial highlights from Fractyl Health, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GUTS?
The investment thesis for GUTS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Fractyl Health, Inc.?
Key executives identified across Fractyl Health, Inc.'s filings include Paul F. Laikind, Barry G. Berman, Joanne E. Smith, Harith Rajagopalan, M.D., Ph.D., Sarah Toomey.
What are the main risk factors for Fractyl Health, Inc. stock?
Of GUTS's 28 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Fractyl Health, Inc.?
Forward guidance and predictions for Fractyl Health, Inc. are extracted from SEC filings as they are enriched.